cobas Influenza A/B Nucleic acid test for use on the cobas Liat System: payments to doctors
Payments that named cobas Influenza A/B Nucleic acid test for use on the cobas Liat System as the associated device or medical supply, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Roche Molecular Systems, Inc.?
Roche Molecular Systems, Inc. reported the most payments naming cobas Influenza A/B Nucleic acid test for use on the cobas Liat System. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $69K
- Providers
- 19
- Transactions
- 24
- Average per transaction
- $2,854
The per-transaction average — $2,854 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 19 providers the average total is $3,606, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Roche Molecular Systems, Inc. | $56,370 | 82.3% |
| Roche Diagnostics Corporation | $12,136 | 17.7% |
Other products from Roche Molecular Systems, Inc.
The company that reported the most payments naming cobas Influenza A/B Nucleic acid test for use on the cobas Liat System also reports against these.
- COBAS INSTRUMENTS & REAGENTS$766,477
- DIAGNOSTICS INFORMATION SYSTEMS$652,616
- MOLECULAR DIAGNOSTICS RESEARCH & DEVELOPMENT$279,416
- CINtec PLUS Cytology$30,001
- cobas 4800 CT/NG Test v2.0$18,000
- cobas 6800 System$6,653
- cobas#x00AE EBV$353
- AVENIO Millisect$274
- BenchMark ULTRA$267